Lexicon PharmaceuticalsLXRX
LXRX
About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Employees: 103
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
236% more call options, than puts
Call options by funds: $547K | Put options by funds: $163K
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
2.5% more ownership
Funds ownership: 79.84% [Q3] → 82.34% (+2.5%) [Q4]
8% less funds holding
Funds holding: 137 [Q3] → 126 (-11) [Q4]
29% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 34
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
51% less capital invested
Capital invested by funds: $453M [Q3] → $220M (-$233M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
96%
upside
Avg. target
$3.67
619%
upside
High target
$6
1,077%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target | 685%upside $4 | Buy Reiterated | 28 Mar 2025 |
Piper Sandler Yasmeen Rahimi 22% 1-year accuracy 5 / 23 met price target | 1,077%upside $6 | Overweight Maintained | 7 Mar 2025 |
Leerink Partners Roanna Ruiz 25% 1-year accuracy 2 / 8 met price target | 96%upside $1 | Market Perform Downgraded | 4 Mar 2025 |
Financial journalist opinion
Based on 5 articles about LXRX published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Neutral
GlobeNewsWire
2 weeks ago
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/.
Positive
Market Watch
3 weeks ago
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
Positive
Benzinga
3 weeks ago
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.
Neutral
GlobeNewsWire
3 weeks ago
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments
Neutral
GlobeNewsWire
1 month ago
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 in Miami on Wednesday, March 12, at 10:00 a.m. ET.
Neutral
Seeking Alpha
1 month ago
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operator Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development
Neutral
GlobeNewsWire
1 month ago
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
Charts implemented using Lightweight Charts™